Purchase this article with an account.
juan c. iturralde, Emil A. Say, Arman Mashayekhi, Sara Lally, Carol L. Shields; Long-term Outcome of Cavitary Retinoblastoma in 22 Patients. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1597.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the long-term ocular and systemic outcome of cavitary retinoblastoma.
Retrospective non-comparative chart review
Twenty-three eyes of 22 patients were included in the study with a median age at presentation of 15 months (range: 3 - 52 months). Fifteen (68%) were male and 7 (32%) were female. Based on the International Classification of Retinoblastoma (ICRB), 11 were classified as group B (48%), 3 were group C (13%), 7 were group D (30%), and 2 were group E (9%). Initial median tumor thickness was 7.1 mm (range, 1.5 - 17.5 mm), while median tumor diameter was 14.5 mm (range: 6.5 - 24.0 mm). Treatment consisted of systemic chemotherapy in 13 patients (59%), enucleation in 3 (14%), intra-arterial chemotherapy in 4 (18%), and observation in 2 (9%). After a median follow-up of 86 months, 22 eyes achieved local tumor control, while one eye (4%) had tumor recurrence treated with enucleation. No patient developed systemic metastasis.
Cavitary retinoblastoma appears to be associated with excellent local and systemic prognosis following chemoreduction or intra-arterial chemotherapy with a 4% risk of local tumor recurrence after a median follow-up of 86 months.
This PDF is available to Subscribers Only